Cachexia Pipeline Review and Therapeutic Development for H2 2015 Available in Market Research Report

Nov 09, 2015, 05:00 ET from ReportsnReports

PUNE, India, November 9, 2015 /PRNewswire/ -- adds "Cachexia - Pipeline Review, H2 2015" to its store. The report provides an overview of the Cachexia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Complete report on Cachexia Pipeline Review spread across 158 pages, analyzing 24 companies and supported with 47 tables and 15 figures is now available at

The report reviews key players involved in the therapeutic development for Cachexia and special features on late-stage and discontinued projects. Companies discussed in this Cachexia - Pipeline Review, H2 2015 report include Acacia Pharma Limited, Aeterna Zentaris Inc., Amgen Inc., Aphios Corporation, Atara Biotherapeutics, Inc., Connexios Life Sciences Pvt. Ltd., Eli Lilly and Company, GlaxoSmithKline Plc, GTx, Inc., Helsinn Healthcare S.A., Incyte Corporation, KAEL-GemVax Co., Ltd., MI.TO. Technology S.r.L., Myos Corporation, Novartis AG, Obexia AG, PolyNovo Limited, PsiOxus Therapeutics Limited, Radius Health, Inc., RaQualia Pharma Inc., Rhythm Pharmaceuticals, VBS Pharmaceuticals, Vicus Therapeutics, LLC and Viking Therapeutics, Inc.

Drug Profiles mentioned in this report are (etodolac + propranolol hydrochloride), (formoterol fumarate + megestrol acetate), anamorelin hydrochloride, Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia, AOD-9604, Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders, ARM-210, ATA-842, AV-380, bimagrumab, C-1889, CAR Peptide, CNX-013B2, DLN-101, dronabinol, Drug to Antagonize ActRIIB for Cancer Cachexia, enobosarm, Espindolol, EXT-400, GSK-2881078, landogrozumab, macimorelin acetate, Monoclonal Antibody to Antagonize TWEAK Receptor for Cachexia and Cancer Cachexia, NBD Peptide, OBX-1201, Proteins for Musculoskeletal Disorders, RAD-140, relamorelin, RQ-00432933, ruxolitinib phosphate, Small Molecule to Agonize Ghrelin Receptor for Cancer Cachexia and Anorexia, Small Molecule to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes, Small Molecules to Inhibit Furin for Sarcopenia and Cachexia, Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia, Small Molecules to Inversely Agonize Beta3-Adrenoreceptor for Cachexia, Metabolic Syndrome and Heart Failure, Small Molecules to Target Melanocortin-4 Receptor for Cachexia, Synthetic Peptide to Inhibit Melanocortin Receptor for Cancer Cachexia, Synthetic Peptides for Cancer Cachexia, tertomotide and VK-5211. Order a copy of this report @ . (This is a premium report priced at US$2000 for a Single User License Copy)

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Cachexia and reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities with key players involved in the therapeutics development for Cachexia and enlists all their major and minor projects. The report summarizes all the dormant and discontinued pipeline projects, review of the Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, a detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Cachexia pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Explore more reports on Pharmaceuticals industry at .

About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect With Us on:  



Twitter: https: //

G+ / Google Plus:



Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441

SOURCE ReportsnReports